Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Sarah Zohar"'
Publikováno v:
Statistics in Medicine
Statistics in Medicine, Wiley-Blackwell, 2021, ⟨10.1002/sim.9113⟩
Statistics in Medicine, 2021, ⟨10.1002/sim.9113⟩
Statistics in Medicine, Wiley-Blackwell, 2021, ⟨10.1002/sim.9113⟩
Statistics in Medicine, 2021, ⟨10.1002/sim.9113⟩
Most phase I trials in oncology aim to find the maximum tolerated dose (MTD) based on the occurrence of dose limiting toxicities (DLT). Evaluating the schedule of administration in addition to the dose may improve drug tolerance. Moreover, for some m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::098f542ec3de29c0699182987d9970a2
https://hal.archives-ouvertes.fr/hal-03335297
https://hal.archives-ouvertes.fr/hal-03335297
Publikováno v:
Annals of Applied Statistics
Annals of Applied Statistics, Institute of Mathematical Statistics, 2021, 15 (1), ⟨10.1214/20-AOAS1390⟩
Annals of Applied Statistics, 2021, 15 (1), ⟨10.1214/20-AOAS1390⟩
Annals of Applied Statistics, Institute of Mathematical Statistics, 2021, 15 (1), ⟨10.1214/20-AOAS1390⟩
Annals of Applied Statistics, 2021, 15 (1), ⟨10.1214/20-AOAS1390⟩
Phase I dose-finding studies aim at identifying the maximal tolerated dose (MTD). It is not uncommon that several dose-finding studies are conducted, although often with some variation in the administration mode or dose panel. For instance, sorafenib
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ef57c2d0a08f1a6b8330cd96b87e7fa3
Autor:
Julien Dupin, Anne Floquet, Roman Rouzier, A. Lesoin, Frédéric Selle, Sandrine Martin-Francoise, Raffaèle Fauvet, Sebastien Gouy, Elisabeth Chereau, Paul Cottu, Pierre-Emmanuel Colombo, Eric Lambaudie, Sarah Zohar, Fabrice Lecuru, Christophe Pomel, Florence Joly, Virginie Fourchotte, Philippe Follana, Y. Ghazi, Elsa Kalbacher
Publikováno v:
European Journal of Cancer
European Journal of Cancer, Elsevier, 2017, 70, pp.133-142. ⟨10.1016/j.ejca.2016.09.036⟩
European Journal of Cancer, 2017, 70, pp.133-142. ⟨10.1016/j.ejca.2016.09.036⟩
European Journal of Cancer, Elsevier, 2017, 70, pp.133-142. ⟨10.1016/j.ejca.2016.09.036⟩
European Journal of Cancer, 2017, 70, pp.133-142. ⟨10.1016/j.ejca.2016.09.036⟩
Aim To investigate whether adding bevacizumab to neoadjuvant carboplatin-paclitaxel (CP) helps achieve optimal debulking, measured by complete resection rate (CRR) at interval debulking surgery (IDS), in patients with initially unresectable Internati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::99fdced170eac0e158a0f444a6d3d1f0
https://hal.archives-ouvertes.fr/hal-01658616
https://hal.archives-ouvertes.fr/hal-01658616
Publikováno v:
Statistical Methods in Medical Research
Statistical Methods in Medical Research, SAGE Publications, 2016, ⟨10.1177/0962280216631763⟩
Statistical Methods in Medical Research, 2016, ⟨10.1177/0962280216631763⟩
Statistical Methods in Medical Research, SAGE Publications, 2016, 〈10.1177/0962280216631763〉
Statistical Methods in Medical Research, SAGE Publications, 2016, ⟨10.1177/0962280216631763⟩
Statistical Methods in Medical Research, 2016, ⟨10.1177/0962280216631763⟩
Statistical Methods in Medical Research, SAGE Publications, 2016, 〈10.1177/0962280216631763〉
International audience; Conventionally, phase I dose-finding trials aim to determine the maximum tolerated dose of a new drug under the assumption that both toxicity and efficacy monotonically increase with the dose. This paradigm, however, is not su
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bcaa0c34d24703ffa3a50683008ba750
https://hal.sorbonne-universite.fr/hal-01298681/document
https://hal.sorbonne-universite.fr/hal-01298681/document
Autor:
S. Puget, Francois P. Doz, Jacques Grill, Nathalie Boddaert, Guillaume Bouchoux, Antoine F. Carpentier, Franck Bourdeaut, K. Beccaria, Christelle Dufour, Michael Canney, Sarah Zohar
Publikováno v:
Neuro-Oncology. 20:i146-i146
OBJECTIVE: To determine the safety of repeated disruption of the blood-brain barrier (BBB) by low intensity pulsed ultrasound (LIPU) with the Sonocloud(®) device in children with recurrent malignant supra-tentorial brain tumors prior to intra-venous
Autor:
Virginie Gandemer, François Demeocq, Claude Dubray, Sylvie Chevret, Pascale Halle, P Le Moine, G Marceau, C Jérôme, N Boiret-Dupré, Catherine Paillard, A. Auvrignon, Etienne Merlin, Sarah Zohar, R. Veyrat-Masson, V Sapin, Justyna Kanold
Publikováno v:
Bone Marrow Transplantation
Bone Marrow Transplantation, 2009, 43 (12), pp.919-25. ⟨10.1038/bmt.2008.412⟩
Bone Marrow Transplantation, Nature Publishing Group, 2009, 43 (12), pp.919-25. ⟨10.1038/bmt.2008.412⟩
Bone Marrow Transplantation, 2009, 43 (12), pp.919-25. ⟨10.1038/bmt.2008.412⟩
Bone Marrow Transplantation, Nature Publishing Group, 2009, 43 (12), pp.919-25. ⟨10.1038/bmt.2008.412⟩
International audience; Our purpose was to assess success rates in children of achieving optimal hematopoietic progenitor cells (HPCs) harvest after mobilization with 300 microg/kg pegfilgrastim. Between January 2005 and January 2007, 26 children wit
Publikováno v:
Computer Methods and Programs in Biomedicine
Computer Methods and Programs in Biomedicine, 2016, 125, pp.117-133. ⟨10.1016/j.cmpb.2015.10.018⟩
Computer Methods and Programs in Biomedicine, Elsevier, 2016, 125, pp.117-133. 〈10.1016/j.cmpb.2015.10.018〉
Computer Methods and Programs in Biomedicine, Elsevier, 2016, 125, pp.117-133. ⟨10.1016/j.cmpb.2015.10.018⟩
Computer Methods and Programs in Biomedicine, 2016, 125, pp.117-133. ⟨10.1016/j.cmpb.2015.10.018⟩
Computer Methods and Programs in Biomedicine, Elsevier, 2016, 125, pp.117-133. 〈10.1016/j.cmpb.2015.10.018〉
Computer Methods and Programs in Biomedicine, Elsevier, 2016, 125, pp.117-133. ⟨10.1016/j.cmpb.2015.10.018⟩
International audience; In this paper, we present the dfcomb R package for the implementation of a single prospective clinical trial or simulation studies of phase I combination trials in oncology. The aim is to present the features of the package an
Autor:
Marisol Urbieta, Eric Leblanc, Paul Cottu, Elisabeth Chereau, Christophe Pomel, Romain Rouzier, Sebastien Gouy, Sarah Zohar, Julien Dupin, Leila Kockler, Sabine Balouet, Florence Joly, Eric Lambaudie, Rose-Marie Ferri, Anne Floquet, Frédéric Selle
Publikováno v:
Journal of Clinical Oncology. 35:5538-5538
5538 Background: ANTHALYA showed that neoadjuvant Bevacizumab (B) added to Carboplatin and Paclitaxel (CP) was well tolerated and achieved encouraging complete resection rates at IDS (58.6%) in unresectable FIGO stage IIIC/IV ovarian, tubal or perito
Autor:
Catherine Uzan, Jean-Rémi Garbay, C. Bezu, Emile Daraï, Emmanuelle Boutmy-Deslandes, Sarah Zohar, Chafika Mazouni, Roman Rouzier, Elisabeth Chereau
Publikováno v:
PLoS ONE
PLoS ONE, Public Library of Science, 2016, 11 (6), pp.e0156096. 〈10.1371/journal.pone.0156096〉
PLoS ONE, 2016, 11 (6), pp.e0156096. ⟨10.1371/journal.pone.0156096⟩
PLoS ONE, Vol 11, Iss 6, p e0156096 (2016)
PLoS ONE, Public Library of Science, 2016, 11 (6), pp.e0156096. ⟨10.1371/journal.pone.0156096⟩
PLoS ONE, Public Library of Science, 2016, 11 (6), pp.e0156096. 〈10.1371/journal.pone.0156096〉
PLoS ONE, 2016, 11 (6), pp.e0156096. ⟨10.1371/journal.pone.0156096⟩
PLoS ONE, Vol 11, Iss 6, p e0156096 (2016)
PLoS ONE, Public Library of Science, 2016, 11 (6), pp.e0156096. ⟨10.1371/journal.pone.0156096⟩
Objective The aim of this study was to assess the efficacy (response rate centered on 80%) of a somatostatin analog with high affinity for 4 somatostatin receptors in reducing the postoperative incidence of symptomatic lymphocele formation following
Publikováno v:
Statistics in Medicine
Statistics in Medicine; Vol 32
Statistics in Medicine; Vol 32
The aim of a phase I oncology trial is to identify a dose with an acceptable safety profile. Most phase I designs use the dose-limiting toxicity, a binary endpoint, to assess the unacceptable level of toxicity. The dose-limiting toxicity might be inc